Fersiynau electronig


  • bistro 2017

    Fersiwn derfynol wedi’i chyhoeddi, 1 MB, dogfen-PDF

Dangosydd eitem ddigidol (DOI)

  • Simon Davies
    Keele University
  • Fergus Caskey
    University of Bristol
  • David Coyle
    Sheffield Teaching Hospitals
  • Elizabeth Lindley
    Sheffield Teaching Hospitals
  • Jamie Macdonald
  • Sandip Mitra
    Sheffield Teaching Hospitals
  • Martin Wilkie
    Sheffield Teaching Hospitals
  • Andrew Davenport
    Royal Free Hampstead NHS Trust
  • Ken Farrington
    East & North Hertfordshire NHS Trust
  • Indranil Dasgupta
    Heart of England NHS Foundation Trust
  • Paula Ormandy
    University of Salford
  • Lazaros Andronis
    University of Birmingham
  • Ivonne Solis-Trapala
    Keele University
  • Julius Sim
    Keele University
Background Preserved residual kidney function (RKF) and normal fluid status are associated with better patient outcomes in incident haemodialysis patients. The objective of this trial is to determine whether using bioimpedance technology in prescribing the optimal post-dialysis weight can reduce the rate of decline of RKF and potentially improve patient outcomes. Methods/Design 516 pateints commencing haemodialysis, aged >18 with RKF of > 3 ml/min/1.73 m2 or a urine volume >500 ml per day or per the shorter inter-dialytic period will be consented and enrolled into a pragmatic, open-label, randomized controlled trial. The intervention is incorporation of bioimpedance spectroscopy (BI) determination of normally hydrated weight to set a post-dialysis target weight that limits volume depletion, compared to current standard practice. Clinicians and participants will be blinded to BI measures in the control group and a standardized record capturing management of fluid status will be used in all participants. Primary outcome is preservation of residual kidney function assessed as time to anuria (≤100 ml/day or ≤200 ml urine volume in the short inter-dialytic period). A sample size of 516 was based upon a cumulative incidence of 30% anuria in the control group and 20% in the treatment group and 11% competing risks (death, transplantation) over 10 months, with up to 2 years follow-up. Secondary outcomes include rate of decline in small solute clearance, significant adverse events, hospitalization, loss of vascular access, cardiovascular events and interventions, dialysis efficacy and safety, dialysis-related symptoms and quality of life. Economic evaluation will be carried out to determine the cost-effectiveness of the intervention. Analyses will be adjusted for patient characteristics and dialysis unit practice patterns relevant to fluid management. Discussion This trial will establish the added value of undertaking BI measures to support clinical management of fluid status and establish the relationship between fluid status and preservation of residual kidney function in incident haemodialysis patients.
Iaith wreiddiolSaesneg
Tudalennau (o-i)138
Nifer y tudalennau11
CyfnodolynBMC Nephrology
Dynodwyr Gwrthrych Digidol (DOIs)
StatwsCyhoeddwyd - 26 Ebr 2017

Cyfanswm lawlrlwytho

Nid oes data ar gael
Gweld graff cysylltiadau